Rates of shared decision-making and PSA testing found to be unequal across sociodemographic groups
“This equation that is true for White men, where more discussion leads to more PSA testing, did not hold for racial minorities,” says Hanan Goldberg, MD, MSc.
In this interview, Hanan Goldberg, MD, MSc, discusses the findings from his study, “Disparities Regarding Shared Decision-Making in Prostate Cancer Screening,” which was presented at the 74th Annual Meeting of the Northeastern Section of the American Urological Association. Goldberg is an assistant professor at SUNY Upstate Medical University.
Lenvatinib/pembrolizumab compares favorably with frontline standards in renal cell carcinoma
February 2nd 2024“Combination therapy with lenvatinib plus pembrolizumab provides a comparable OS, and a trend of improvement in PFS and response outcomes, compared with most current global SOC therapies for treatment-naïve patients with advanced renal cell carcinoma,” the study authors wrote.
First-line pembrolizumab/lenvatinib shows efficacy for advanced non–clear cell RCC
January 29th 2024“Updated efficacy and safety results continue to support pembrolizumab plus lenvatinib as a first-line treatment option for patients with advanced non–clear cell RCC,” lead study author Martin H. Voss, MD.
